# Takeda Pharmaceutical Company Limited American (TAK) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Pharmaceuticals. Price $18.45, market value $58.9 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Takeda Pharmaceutical Company Limited American reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 2.0×**. Each dollar of revenue is priced at 2.0×.
- **Price / book: 1.2×**. The shares trade at 1.2× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 20.7×**. Enterprise value is 20.7× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 5.3%**. Free cash flow equals 5.3% of the market value. Above 5% is generally attractive.

## Profitability
- **Gross margin: 65.5%**. Takeda Pharmaceutical Company Limited American keeps 65.5% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 10.4%**. 10.4% of revenue is left after running the business.
- **Net margin: -3.4%**. The company reported a net loss over the last twelve months.
- **Return on equity: -2.1%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 4.1%**. Return on all capital, debt included, is 4.1%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -1.1%**. Each dollar of assets produces -1.1% of profit.

## Growth
- **Revenue growth (1 yr): -1.7%** (3-yr 3.8%/yr, 5-yr 7.1%/yr). Revenue fell 1.7% over the last year, against 7.1% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -11.0%** (3-yr -33.3%/yr, 5-yr -24.2%/yr). Earnings per share fell 11.0%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): -9.2%/yr**. Free cash flow has compounded at -9.2% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.66**. Debt is 0.66 times equity, moderate leverage.
- **Net debt / EBITDA: 6.6×**. It would take 6.6 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Interest coverage: 4.6×**. Operating profit covers interest 4.6× over, a safe margin.
- **Current ratio: 1.09** (quick 0.60). Current assets cover the next year's liabilities 1.09 times.
- **Altman Z-score: 1.08**. A Z-score of 1.08 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend yield: 3.34%** ($0.62 per share, trailing). Takeda Pharmaceutical Company Limited American yields 3.34%, a modest yield more typical of a growth-oriented payer.

## Analyst view
- **Analyst consensus: strong_buy** (3 analysts). 3 analysts cover Takeda Pharmaceutical Company Limited American; the consensus is strong_buy, with an average price target of $22.43 (+22% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 20.7%** (YTD 18.3%, 3-mo 18.3%). The shares are up 20.7% over twelve months including dividends.
- **From 52-week high: -2.4%** (42.0% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 62**. An RSI of 62 is neutral.
- **Beta (1 yr): 0.21** (volatility 21%). Beta of 0.21 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=TAK · Page: https://foliofundamentals.com/stocks/tak

Not investment advice.